Drug Profile
Research programme: influenza virus vaccines - Vaxart
Alternative Names: Avian influenza quadrivalent vaccine - Vaxart; Bird flu quadrivalent vaccine - Vaxart; H1N1 swine influenza vaccine - Vaxart; H3N2 seasonal influenza vaccine - Vaxart; H5N1 avian influenza virus quadrivalent vaccine - Vaxart; H7N9 avian influenza vaccine - Vaxart; Oral adenovirus-based quadrivalent avian flu influenza vaccine - Vaxart; Oral quadrivalent seasonal influenza vaccine - Vaxart; Pandemic H5N1 influenza A virus quadrivalent vaccine - VaxartLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Vaxart
- Class Influenza virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H3N2 subtype; Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype
- Discontinued Influenza A virus H1N1 subtype
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype(Prevention) in USA (PO, Tablet)
- 24 Feb 2021 Vaxart files for patent protection for proprietary technology, VAAST™ platform, and creations for oral vaccination using adenovirus and TLR3 agonists in USA and other countries
- 13 Apr 2019 Pharmacodynamics data from a preclinical study in Influenza A virus H5N1 subtype presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2019)